Characterization of tetrandrine, a potent inhibitor of P-glycoprotein- mediated multidrug resistance

Cancer Chemotherapy and Pharmacology

Volumn 53, Issue 4, 2004, Pages 349-356

  Fu, Liwu ^a   Liang, Yongju ^a   Deng, Liwen ^b   Ding, Yan ^a   Chen, Liming ^a   Ye, Yanli ^a   Yang, Xiaoping ^a   Pan, Qichao ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Multidrug resistance; Nude mice; P glycoprotein; Tetrandrine; Vincristine; Xenograft

Indexed keywords

AZIDOPINE; GLYCOPROTEIN P; TETRANDRINE; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER GRAFT; CANCER INHIBITION; CANCER RESISTANCE; CELL STRAIN KB; CONTROLLED STUDY; DRUG POTENTIATION; MALE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; NUDE MOUSE; PHOTOAFFINITY LABELING; PRIORITY JOURNAL;

ALKALOIDS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BENZYLISOQUINOLINES; CARCINOMA, SQUAMOUS CELL; CELL MEMBRANE; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; KB CELLS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; P-GLYCOPROTEINS; PROTEIN BINDING; VINCRISTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 1642299307     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0742-5     Document Type: Article

References (31)

1. Atadja P, Watanabe T, Xu H, Cohen D (1998) PSC-833, a frontier in modulation of P-glycoprotein mediated multidrug resistance. Cancer Metastasis Rev 17:163-168
2. Carmichael J, DeGraff WG, Gazadar AF, Minna JD, Mitchell JB (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47:943-946
3. Chen ZS, Kawabe T, Ono M, Aoki S, Sumizawa T, Furukawa T, Uchiumi T, Wada M, Kuwano M, Akiyama SI (1999) Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol Pharmacol 56:1219-1228
4. Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, Baughman TM, Bumol TF, Starling JJ (1996) Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 56:4171-4179
5. Fang JH, Fang YH (1996) Tetrandrine: pharmacology and clinical usefulness. Chin Pharm J 31:454-457
6. Fu LW, Pan QC (1996) The properties shared by compounds with reversing tumor multidrug resistance. Chin J Cancer 15:475-477
7. Fu LW, He LR, Liang YJ, Chen LM, Xiong HY, Yang XP, Pan QC (2003) Experimental chemotherapy against xenografts derived from multidrug resistant KBv200 cells and parental drug-sensitive KB cells in nude mice by annonaceous acetogenin 89-2. Yao Xue Xue Bao 38:565-570
8. Germann UA, Shlyakhter D, Mason VS, Zelle RE, Duffy JP, Galullo V, Armistead DM, Saunders JO, Boger J, Harding MW (1997) Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs 8:125-140
9. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T (1993) In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53:4595-4602
10. Krishna R, Mayer LD (2000) Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 11:265-283
11. Lawrence DS, Copper JE, Smith CD (2001) Structure-activity studies of substituted quinoxalinones as multiple-drug-resistance antagonists. J Med Chem 44:594-601
12. Lella JW (2001) Constructing history in biography: a symposium on William Osler: a life in medicine. Introduction. Bull Hist Med 75:740-744
13. Liang YJ, Fu Lw, Pan QC (2000) Establishment of the model of KBv200 nude mice xenograft and the studies on its characterization of multidrug resistance. Chin Pharmacol Bull 16:705-707
14. Ling V (1997) Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol [Suppl] 40:S3
15. Malayeri R, Filipits M, Suchomel RW, Zochbauer S, Lechner K, Pirker R (1996) Multidrug resistance in leukemias and its reversal. Leuk Lymphoma 23:451-458
16. May GL, Wright LC, Dyne M, Mackinnon WB, Fox RM, Mountford CE (1988) Plasma membrane lipid composition of vinblastine sensitive and resistant human leukaemic lymphoblasts. Int J Cancer 42:728-733
17. Motoji T, Motomura S, Wang YH (2000) Multidrug resistance of acute leukemia and a strategy to overcome it. Int J Hematol 72:418-424
18. Newman MJ, Rodarte JC, Benbatoul KD, Romano SJ, Zhang C, Krane S, Moran EJ, Uyeda RT, Dixon R, Guns ES, Mayer LD (2000) Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res 60:2964-2972
19. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen TH, van Kalken CK, Slovak ML, de Vries EG, van der Valk P (1993) Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein- mediated multidrug resistance. Cancer Res 53:1475-1479
20. Sikic BI (1997) Pharmacologic approaches to reversing multidrug resistance. Semin Hematol 34 [4 Suppl 5]:40-47
21. Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G (1997) Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol [Suppl] 40:S13-19
22. Starling JJ, Shepard RL, Cao J, Law KL, Norman BH, Kroin JS, Ehlhardt WJ, Baughman TM, Winter MA, Bell MG, Shih C, Gruber J, Elmquist WF, Dantzig AH (1997) Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein. Adv Enzyme Regul 37:335-347
23. Sumizawa T, Chen ZS, Chuman Y, Seto K, Furukawa T, Haraguchi M, Tani A, Shudo N, Akiyama SI (1997) Reversal of multidrug resistance-associated protein-mediated drug resistance by the pyridine analog PAK-104P. Mol Pharmacol 51:399-405
24. Szabo D, Keyzer H, Kaiser HE, Molnar J (2000) Reversal of multidrug resistance of tumor cells. Anticancer Res 20:4261-4274
25. Tranchand B, Catimel G, Lucas C, Sarkany M, Bastian G, Evene E, Guastalla JP, Negrier S, Rebattu P, Dumortier A, Foy M, Grossin F, Mazier B, Froudarakis M, Barbet N, Clavel M, Ardiet C (1998) Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors. Cancer Chemother Pharmacol 41:281-291
26. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967-1972
27. van den Heuvel-Eibrink MM, Sonneveld P, Pieters R (2000) The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia. Int J Clin Pharmacol Ther 38:94-110
28. Volm M (1998) Multidrug resistance and its reversal. Anticancer Res 18:2905-2917
29. Wiese M, Pajeva IK (2001) Structure-activity relationships of multidrug resistance reversers. Curr Med Chem 8:685-713
30. Wigler PW (1996) Cellular drug efflux and reversal therapy of cancer. J Bioenerg Biomembr 28:279-284
31. Zhang XH, Zhang FY, Ji XJ, Li ZY (1994) Vincristine-resistant human KB cell line and mechanism of multidrug resistance. Yao Xue Xue Bao 29:246-251